Bima Paolo, Lopez-Ayala Pedro, Koechlin Luca, Boeddinghaus Jasper, Nestelberger Thomas, Okamura Bernhard, Muench-Gerber Tamar S, Sanzone Alessandra, Skolozubova Daria, Djurdjevic David, Rubini Gimenez Maria, Wildi Karin, Miro Oscar, Martínez-Nadal Gemma, Martin-Sanchez Francisco J, Christ Michael, Keller Dagmar, Lindahl Bertil, Giannitsis Evangelos, Mueller Christian
Cardiovascular Research Institute Basel and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
GREAT Network, Rome, Italy.
JACC CardioOncol. 2023 Aug 26;5(5):591-609. doi: 10.1016/j.jaccao.2023.08.001. eCollection 2023 Oct.
Little is known about patients with cancer presenting with acute chest discomfort to the emergency department (ED).
The aim of this study was to assess the prevalence of acute myocardial infarction (AMI), outcomes, and the diagnostic utility of recommended diagnostic tools in this population.
Patients presenting with chest pain to the ED were prospectively enrolled in an international multicenter diagnostic study with central adjudication. Cancer status was assessed prospectively and additional cancer details retrospectively. Findings were externally validated in an independent multicenter cohort.
Among 8,267 patients, 711 (8.6%) had cancer. Patients with cancer had a higher burden of cardiovascular risk factors and pre-existing cardiac disease. Total length of stay in the ED (5.2 hours vs 4.3 hours) and hospitalization rate (49.8% vs 34.3%) were both increased in patients with cancer ( < 0.001 for both). Among 8,093 patients eligible for the AMI analyses, those with cancer more often had final diagnoses of AMI (184 of 686 with cancer [26.8%] vs 1,561 of 7,407 without cancer [21.1%]; < 0.001). In patients with cancer, high-sensitivity cardiac troponin T (hs-cTnT) but not high sensitivity cardiac troponin I (hs-cTnI) concentration had lower diagnostic accuracy for non-ST-segment elevation myocardial infarction (for hs-cTnT, area under the curve: 0.89 [95% CI: 0.86-0.92] vs 0.94 [95% CI: 0.93-0.94] [ < 0.001]; for hs-cTnI, area under the curve: 0.93 [95% CI: 0.91-0.95] vs 0.95 [95% CI: 0.94-0.95] [P = 0.10]). In patients with cancer, the European Society of Cardiology 0/1-hour hs-cTnT and hs-cTnI algorithms maintained very high safety but had lower efficacy, with twice the number of patients remaining in the observe zone. Similar findings were obtained in the external validation cohort.
Patients with cancer have a substantially higher prevalence of AMI as the cause of chest pain. Length of ED stay and hospitalization rates are increased. The diagnostic performance of hs-cTnT and the efficacy of both the European Society of Cardiology 0/1-hour hs-cTnT and hs-cTnI algorithms is reduced. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study; NCT00470587).
对于因急性胸部不适前往急诊科(ED)就诊的癌症患者,我们知之甚少。
本研究旨在评估该人群中急性心肌梗死(AMI)的患病率、结局以及推荐诊断工具的诊断效用。
前瞻性纳入因胸痛前往ED就诊的患者,进行一项国际多中心诊断研究,并由中心进行判定。前瞻性评估癌症状态,回顾性收集额外的癌症细节。研究结果在一个独立的多中心队列中进行外部验证。
在8267例患者中,711例(8.6%)患有癌症。癌症患者心血管危险因素和既往存在的心脏病负担更高。癌症患者在ED的总住院时间(5.2小时 vs 4.3小时)和住院率(49.8% vs 34.3%)均增加(两者均P<0.001)。在8093例符合AMI分析条件的患者中,癌症患者最终诊断为AMI的比例更高(686例癌症患者中有184例[26.8%],7407例非癌症患者中有1561例[21.1%];P<0.001)。在癌症患者中,高敏心肌肌钙蛋白T(hs-cTnT)而非高敏心肌肌钙蛋白I(hs-cTnI)浓度对非ST段抬高型心肌梗死的诊断准确性较低(对于hs-cTnT,曲线下面积:0.89[95%CI:0.86 - 0.92] vs 0.94[95%CI:0.93 - 0.94][P<0.001];对于hs-cTnI,曲线下面积:0.93[95%CI:0.91 - 0.95] vs 0.95[95%CI:0.94 - 0.95][P = 0.10])。在癌症患者中,欧洲心脏病学会0/1小时hs-cTnT和hs-cTnI算法保持了非常高的安全性,但有效性较低,留在观察区的患者数量增加了一倍。在外部验证队列中也获得了类似的结果。
癌症患者因胸痛导致AMI的患病率显著更高。ED住院时间和住院率增加。hs-cTnT的诊断性能以及欧洲心脏病学会0/1小时hs-cTnT和hs-cTnI算法的有效性均降低。(急性冠状动脉综合征评估优势预测因子[APACE]研究;NCT00470587)